Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome

Journal of Interferon and Cytokine Research

Volumn 17, Issue 7, 1997, Pages 377-385

  Suhadolnik, Robert J ^a   Peterson, Daniel L ^b   O'Brien, Karen ^b   Cheney, Paul R ^c   Herst, C V T ^a   Reichenbach, Nancy L ^a   Kon, Ning ^a   Horvath, Susan E ^a   Iacono, Kathryn T ^a   Adelson, Martin E ^a   De Meirleir, Kenny ^d   De Becker, Pascale ^d   Charubala, Ramamurthy ^e   Pfleiderer, Wolfgang ^e  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sierra Internal Medicine Associates   (United States)

^c Cheney Clinic   (United States)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC FATIGUE SYNDROME; PRIORITY JOURNAL;

EID: 0030863581     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1997.17.377     Document Type: Article

References (37)

1. HOLMES, G.P., KAPLAN, J.E., GLANTZ, N.M., KOMAROFF, A.L., SCHONBERGER, L.B., STRAUS, S.E., JONES, J.F., DUBOIS, R.E., CUNNINGHAM-RUNDLES, C., PAHWA, S., TOSATO, G., ZEGANO, L.S., PURTILO, D.T., BROWN, N., SCHOOLEY, R.T., and BRIS, I. (1988). Chronic fatigue syndrome: a working case definition. Ann. Intern. Med. 108, 387-389.
2. FUKUDA, K., STRAUS, S.E., HICKIE, I., SHARPE, M.C., DOBBINS, J.G., and KOMAROFF, A. (1994). .International Chronic Fatigue Syndrome Study Group. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann. Intern. Med. 121, 953-959.
3. BATES, D., BUCHWALD, D., LEE, J., KITH, P., DOOLITTLE, T., RUTHERFORD, C., CHURCHILL, W.H., SCHUR, P.H., WENER, M., WYBENGA, D., WINKELMAN, J., and KOMAROFF, A.L. (1995). Clinical laboratory test findings in patients with chronic fatigue syndrome. Arch. Intern. Med.l 155, 97-103.
4. CHAO, C.C., JANOFF, E.N., HU, S.X., THOMAS, K., GALLAGHER, M., TSANG, M., and PETERSON, P.K. (1991). Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 3, 292-298.
5. McGREGOR, N.R., DUNSTAN, R.H., ZERBES, M., BUTT, H.L., ROBERTS, T.K., and KLINEBERG, I.J. (1996). Preliminary determination of a molecular basis to chronic fatigue syndrome. Biochem. Mol. Med. 57, 73-80.
6. LEVY, J.A. (1994). Viral studies of chronic fatigue syndrome. Clin. Infect. Dis. 18, S117-S120.
7. STRAUS, S., FRITZ, S., DALE, J., GOULD, B., and STROBER, W. (1993). Lymphocyte phenotype and function in the chronic fatigue syndrome. J. Clin. Immunol. 13, 30-40.
8. DEMITRACK, M., DALE, J., STRAUS, S., LAUE, L., LISTWAK, S., KRUESI, M., CHROUSOS, G., and GOLD, P. (1991). Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinol. Metab. 73, 1224-1234.
9. CALIGUlRI, M., MURRAY, C., BUCHWALD, D., LEVINE, H., CHENEY, P., PETERSON, D., KOMAROFF, A., and RITZ, J. (1987). Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J. Immunol. 139, 3306-3313.
10. BUCHWALD, D., and KOMAROFF, A.L. (1991). Review of laboratory findings for patients with chronic fatigue syndrome. Rev. Infect. Dis. 13(Suppl. 1), S12-S18.
11. JONES, J., RAY, C., MINNICH, L., HICKS, M., KIBLER, R., and LUCAS, D. (1985). Evidence of active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann. Intern. Med. 102, 1-7.
12. KLIMUS, N.G., SALVATO, F.R., MORGAN, R., and FLETCHER, M.A. (1990). Immunologic abnormalities in chronic fatigue syndrome. J. Clin. Microbiol. 28, 1403-1410.
13. SEE, D.M., and TILLES, J.G. (1996). Alpha interferon treatment of patients with chronic fatigue syndrome. Immunol. Invest. 25, 153-164.
14. SUHADOLNIK, R.J., REICHENBACH, N.L., HITZGES, P., SOBOL, R.W., PETERSON, D.L., HENRY, B., ABLASHI, D.V., MÜLLER, W.E.G., SCHRÖDER, H.C., CARTER, W.A., and STRAYER, D.R. (1994). Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin. Infect. Dis. 18, S96-S104.
15. 12U) in chronic fatigue syndrome. In Vivo 8, 599-604.
16. LENGYEL, P. (1982). Biochemistry of interferons and their actions. Annu. Rev. Biochem. 51, 251-282.
17. SEN, G.C., and RANSOHOFF, R.M. (1993). Interferon-induced antiviral actions and their regulation. Adv. Virus Res. 42, 57-102.
18. WELLS, V., and MALLUCCI, L. (1985). Expression of the 2-5A system during the cell cycle. Exp. Cell Res. 159, 27-36.
19. BISBAL, C., MARTINAND, C., SILHOL, M., LEBLEU, B., and SALEHZADA, T. (1995). Cloning and characterization of a RNase L inhibitor, a new component of the interferon-regulated 2-5A pathway. J. Biol. Chem. 270, 13308-13317.
20. 32P]ATP. J. Biol. Chem. 271, 19983-19990.
21. SOBOL, R.W., HENDERSON, E.E., KON, N., SHAO, J., HITZGES, P., MORDECHAI, E., REICHENBACH, N.L., CHARUBALA, R., SCHIRMEISTER, H., PFLEIDERER, W., and SUHADOLNIK, R.J. (1995). Inhibition of HIV-1 replication and activation of RNase L by phosphorothioate/phosphodiester 2′,5′-oligoadenylate derivatives. J. Biol. Chem. 270, 5963-5978.
22. 8A. Helv. Chim. Acta 72, 1354-1361.
23. DONG, B., XU, L., ZHOU, A., HASSEL, B.A., LEE, X., TORRENCE, P.F., and SILVERMAN, R.H. (1994). Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J. Biol. Chem. 269, 14153-14158.
24. SOMERVILLE, C.C., NISHINO, S.F., and SPAIN, J.D. (1995). Purification and characterization of nitrobenzene nitroreductase from Pseudomonas pseudoalcaligenes JS45. J. Bacteriol. 177, 3837-3842.
25. n-dependent endonucleases of different molecular mass. Eur. J. Biochem. 479, 959-602.
26. SILVERMAN, R.H., JUNG, D.D., NOLAN-SORDEN, N.L., DIEFFENBACH, C.W., KEDAR, V.P., and SEN-GUPTA, D.N. (1988). Purification and analysis of murine 2-5A-dependent RNase. J. Biol. Chem. 263, 7336-7342.
27. HOVANESSIAN, A.G., LAURENT, A.G., CHEBATH, J., GALABRU, J., ROBERT, N., and SVAB, J. (1987). Identification of 69-kd and 100-kd Forms of 2-5A synthetases in interferon-treated human cells by specific monoclonal antibodies. EMBO J. 6, 1273-12809.
28. n A-binding proteins and interferon-related enzymes in animals, plants, and lower organisms. Biochem. Biophys. Res. Commun. 108, 1243-1250.
29. DIRIONG, S., SALEHZADA, T., BISBAL, C., MARTINAND, C., and TAVIAUX, S. (1996). Localization of the ribonuclease L inhibitor gene (RNS41), a new member of the interferon-regulated 2-5A pathway, to 4q31 by fluorescence in situ hybridization. Genomics 32, 488-490.
30. AUBRY, F., MATTEI, M.-G., BARQUE, J.-P., and GALIBERT, F. (1996). Chromosomal localization and expression pattern of the RNase L inhibitor gene. FEBS Lett. 381, 135-139.
31. STARK, G., DOWER, W.J., SCHIMKE, R.T., BROWN, R.E., and KERR, I.M. (1979). 2-5A Synthetase: assay, distribution and variation with growth or hormone status. Nature 278, 471-478.
32. nA-dependent RNase levels during interferon treatment and cell differentiation. Eur. J. Biochem. 146, 611-618.
33. n-dependent ribonucleases in cell extracts by ultraviolet irradiation. J. Biol. Chem. 257, 8584-8587.
34. CARROLL, S.S., CHEN. E., VISCOUNT, T., GEIB, J., SARDANA, M.K., GEHMAN, J., and KUO, L.C. (1996). Cleavage of oligoribonucleotides by the 2′,5′-oligoadenylate-dependent ribonuclease L. J. Biol. Chem. 271, 4983-4992.
35. 31P nuclear magnetic resonance spectroscopy. Chest 102, 1716-1722.
36. KARIKO, K., LI, S.W., SOBOL, R.W., JR., SUHADOLNIK, R.J., CHARUBALA, R., and PFLEIDERER, W. (1987). Phosphorothioate analogues of 2′,5-oligoadenylate. Activation of 2′-5′-oligoadenylate-dependent endoribonuclease by 2′,5′-phosphorothioate cores and 5′-monophosphates. Biochemistry 26, 7136-7142.
37. 4): agonist and antagonist activities in intact cells. Biochemistry 29,2550-2556.